Home/Filings/4/0001415889-22-002868
4//SEC Filing

Englese Thomas 4

Accession 0001415889-22-002868

CIK 0001708527other

Filed

Mar 9, 7:00 PM ET

Accepted

Mar 10, 8:46 PM ET

Size

16.5 KB

Accession

0001415889-22-002868

Insider Transaction Report

Form 4
Period: 2022-03-08
Englese Thomas
Chief Commercial Officer
Transactions
  • Award

    Restricted Stock Units

    2022-03-08+8,7008,700 total
    Class A Common Stock (8,700 underlying)
  • Award

    Restricted Stock Units

    2022-03-08+15,39015,390 total
    Class A Common Stock (15,390 underlying)
  • Sale

    Class A Common Stock

    2022-03-102766,607 total
  • Award

    Stock Option (Right to Buy)

    2022-03-08+31,00031,000 total
    Exercise: $5.08Exp: 2032-03-08Class A Common Stock (31,000 underlying)
  • Exercise/Conversion

    Class A Common Stock

    2022-03-08+9386,883 total
  • Exercise/Conversion

    Restricted Stock Units

    2022-03-089382,812 total
    Class A Common Stock (938 underlying)
Footnotes (8)
  • [F1]Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.
  • [F2]Includes 857 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.16 to $5.34. The Reporting Person undertakes to provide Aziyo Biologics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F4]The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026.
  • [F5]Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.
  • [F6]The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.
  • [F7]On March 8, 2021, the Reporting Person was granted 3,750 restricted stock units, vesting in four substantially equal annual installments beginning in March 8, 2022.
  • [F8]The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

Issuer

AZIYO BIOLOGICS, INC.

CIK 0001708527

Entity typeother

Related Parties

1
  • filerCIK 0001825799

Filing Metadata

Form type
4
Filed
Mar 9, 7:00 PM ET
Accepted
Mar 10, 8:46 PM ET
Size
16.5 KB